Back to all Programs

Register here

Related Materials

Past event

International Workshop on HBV Cure 2023

Viral Hepatitis and Liver Disease

Durability of Response After DAA Therapies - Fabien Zoulim, MD, PhD

Viral Hepatitis and Liver Disease

Expanding CHB Treatment Criteria with Nucs as Prelude of Novel Curative Therapies? - Harry Janssen, MD, PhD

Viral Hepatitis and Liver Disease

Are We Only Able to Suppress HDV or is Cure in Reach? - Pietro Lampertico, MD, PhD

Viral Hepatitis and Liver Disease

Latest Updates on Novel Biomarkers in HBV Cure - Man-Fung Yuen, MBBS, MD, PhD, DSc

Viral Hepatitis and Liver Disease

Next Generation CAMs, New Life for Small Molecules? - Mark Sulkowski, MD

Viral Hepatitis and Liver Disease

Balance of Response and Adverse Events in Immunotherapy for CHB - Jordan Feld, MD, MPH

Viral Hepatitis and Liver Disease

Immunological Profiles Induced by New Therapeutic Vaccines - Eleanor Barnes, PhD, FRCP, F. Med. Sci.

Viral Hepatitis and Liver Disease

Efficacy and Safety of Targeting PD-L1 with Monoclonal Antibodies - Jinzi J. Wu, Ph.D.

Viral Hepatitis and Liver Disease

Value of Adding Recombinant Antigens to Viral Vector Vaccines - Ventzi Vassilev, PhD

Viral Hepatitis and Liver Disease

Anti-HBs Monoclonal Antibodes in Nuc-naïve and Combo Therapies - Carey Hwang, MD, PhD

Viral Hepatitis and Liver Disease

Discrimination of Integrated vs. cccDNA Derived HBsAg - Chloe Thio, MD

Viral Hepatitis and Liver Disease

Does siRNA Restore Host Control and Could it Lead to Sustained HBsAg Suppression? - Michael J. Sofia, Ph.D

Viral Hepatitis and Liver Disease

Second Generation CAMs Leading to HBsAg Decline - Matthew McClure, MD

Viral Hepatitis and Liver Disease

Bepirovirsen in Combination with Peg-IFN and Other Molecules - Stuart Kendrick, MD, PhD, MRCP

Viral Hepatitis and Liver Disease

20 Selected HBV-related Abstracts Being Presented at AASLD 2023 - Adam Gehring, PhD